General pharmacological studies on Biapenem

General pharmacological properties of biapenem (BIPM), a new carbapenem antibiotic, were studiedand the following results were obtained. 1. BIPM at doses of 10-1000mg/kg i.v. caused no influences on the gross behavior of mice.Neither 30 nor 100 mg/kg i.v. of BIPM affected the spontaneous motor activ...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 42; no. Supplement4; pp. 216 - 228
Main Authors Shiba, Toshiharu, Shikata, Yoshiyuki, Ishikawa, Tomokazu, Yanaka, Masao, Kitazumi, Kazuhiro, Ito, Mami
Format Journal Article
LanguageEnglish
Japanese
Published Japanese Society of Chemotherapy 1994
公益社団法人 日本化学療法学会
Subjects
Online AccessGet full text
ISSN0009-3165
1884-5894
DOI10.11250/chemotherapy1953.42.Supplement4_216

Cover

Abstract General pharmacological properties of biapenem (BIPM), a new carbapenem antibiotic, were studiedand the following results were obtained. 1. BIPM at doses of 10-1000mg/kg i.v. caused no influences on the gross behavior of mice.Neither 30 nor 100 mg/kg i.v. of BIPM affected the spontaneous motor activity, thiopental-induced hypnosis and pentylenetetrazole strychnine-and electroshock-induced convulsive reactions in mice. Furthermore, the same doses of BIPM showed no effects on normal body temperature and pressure-pain threshold in the inflamed paw of rats. BIPM at a dose of 300 mg/kg i.v. had no influences on the spontaneous EEG pattern in rabbits and at doses up to 600 mg/kg i.v. had no potentiation of pentylenetetrazole-induced convulsive activity in mice. In addition, intracerebroventricular injection of BIPM at doses up to 300 μg/animal did not produce behavioral changes in mice. By contrast, imipenem/cilastatin sodium at a dose of 150/150 mg/kg i.v. and above potentiated the pentylenetetrazole-induced convulsive activity and imipenem injected intracerebroventricularly at a dose of 10 μg/animal and above elicited convulsive behaviors in mice. 2. BIPM at a dose of 100 mg/kg i.v. slightly caused a decrease followed by a increase in blood pressure and increases in heart rate and femoral arterial blood flow without any changes in ECG and respiratory movement in anesthetized dogs, whereas this compound at a dose of 30 mg/kg i.v. elicited no effects on parameters. BIPM at a concentration of 10 -4M exerted no influences on contractile force, beating rate and coronary flow of isolated perfused rat hearts. 3. BIPM at a concentration of 10-4 g/ml (2.9 × 10-4M) did not influence the spontaneous motility and the contractile responses induced by acetylcholine, histamine, serotonin and barium chloride of isolated guinea pig ileums. Furthermore, BIPM at doses up to 100 mg/kg i.v. showed no effects on propulsion of gastrointestinal tract in mice and on airway resistance in anesthetized guinea pigs. 4. BIPM at doses up to 100mg/kg i.v.showed no influences on urine volume and Na+, K+and Cl-excretion in rats. A delay of BSP excretion in rats were observed at 100 mg/kg i.v. of BIPM, but notat 30 mg/kg i. v. 5. BIPM at a concentration of 10-4M did not influence the platelet aggregation by ADP and collagen, the plasma coagulation and the hemolysis test in rabbits. These findings suggest that BIPM seems to be much less potent than imipenem/cilastatin sodium in inducing proconvulsive activity and has no remarkable adverse actions regarding this general pharmacological study.
AbstractList General pharmacological properties of biapenem (BIPM), a new carbapenem antibiotic, were studiedand the following results were obtained. 1. BIPM at doses of 10-1000mg/kg i.v. caused no influences on the gross behavior of mice.Neither 30 nor 100 mg/kg i.v. of BIPM affected the spontaneous motor activity, thiopental-induced hypnosis and pentylenetetrazole strychnine-and electroshock-induced convulsive reactions in mice. Furthermore, the same doses of BIPM showed no effects on normal body temperature and pressure-pain threshold in the inflamed paw of rats. BIPM at a dose of 300 mg/kg i.v. had no influences on the spontaneous EEG pattern in rabbits and at doses up to 600 mg/kg i.v. had no potentiation of pentylenetetrazole-induced convulsive activity in mice. In addition, intracerebroventricular injection of BIPM at doses up to 300 μg/animal did not produce behavioral changes in mice. By contrast, imipenem/cilastatin sodium at a dose of 150/150 mg/kg i.v. and above potentiated the pentylenetetrazole-induced convulsive activity and imipenem injected intracerebroventricularly at a dose of 10 μg/animal and above elicited convulsive behaviors in mice. 2. BIPM at a dose of 100 mg/kg i.v. slightly caused a decrease followed by a increase in blood pressure and increases in heart rate and femoral arterial blood flow without any changes in ECG and respiratory movement in anesthetized dogs, whereas this compound at a dose of 30 mg/kg i.v. elicited no effects on parameters. BIPM at a concentration of 10 -4M exerted no influences on contractile force, beating rate and coronary flow of isolated perfused rat hearts. 3. BIPM at a concentration of 10-4 g/ml (2.9 × 10-4M) did not influence the spontaneous motility and the contractile responses induced by acetylcholine, histamine, serotonin and barium chloride of isolated guinea pig ileums. Furthermore, BIPM at doses up to 100 mg/kg i.v. showed no effects on propulsion of gastrointestinal tract in mice and on airway resistance in anesthetized guinea pigs. 4. BIPM at doses up to 100mg/kg i.v.showed no influences on urine volume and Na+, K+and Cl-excretion in rats. A delay of BSP excretion in rats were observed at 100 mg/kg i.v. of BIPM, but notat 30 mg/kg i. v. 5. BIPM at a concentration of 10-4M did not influence the platelet aggregation by ADP and collagen, the plasma coagulation and the hemolysis test in rabbits. These findings suggest that BIPM seems to be much less potent than imipenem/cilastatin sodium in inducing proconvulsive activity and has no remarkable adverse actions regarding this general pharmacological study.
General pharmacological properties of biapenem (BIPM), a new carbapenem antibiotic, were studiedand the following results were obtained.1. BIPM at doses of 10-1000mg/kg i.v. caused no influences on the gross behavior of mice.Neither 30 nor 100 mg/kg i.v. of BIPM affected the spontaneous motor activity, thiopental-induced hypnosis and pentylenetetrazole strychnine-and electroshock-induced convulsive reactions in mice. Furthermore, the same doses of BIPM showed no effects on normal body temperature and pressure-pain threshold in the inflamed paw of rats. BIPM at a dose of 300 mg/kg i.v. had no influences on the spontaneous EEG pattern in rabbits and at doses up to 600 mg/kg i.v. had no potentiation of pentylenetetrazole-induced convulsive activity in mice. In addition, intracerebroventricular injection of BIPM at doses up to 300 μg/animal did not produce behavioral changes in mice. By contrast, imipenem/cilastatin sodium at a dose of 150/150 mg/kg i.v. and above potentiated the pentylenetetrazole-induced convulsive activity and imipenem injected intracerebroventricularly at a dose of 10 μg/animal and above elicited convulsive behaviors in mice.2. BIPM at a dose of 100 mg/kg i.v. slightly caused a decrease followed by a increase in blood pressure and increases in heart rate and femoral arterial blood flow without any changes in ECG and respiratory movement in anesthetized dogs, whereas this compound at a dose of 30 mg/kg i.v. elicited no effects on parameters. BIPM at a concentration of 10 -4M exerted no influences on contractile force, beating rate and coronary flow of isolated perfused rat hearts.3. BIPM at a concentration of 10-4 g/ml (2.9 × 10-4M) did not influence the spontaneous motility and the contractile responses induced by acetylcholine, histamine, serotonin and barium chloride of isolated guinea pig ileums. Furthermore, BIPM at doses up to 100 mg/kg i.v. showed no effects on propulsion of gastrointestinal tract in mice and on airway resistance in anesthetized guinea pigs.4. BIPM at doses up to 100mg/kg i.v.showed no influences on urine volume and Na+, K+and Cl-excretion in rats. A delay of BSP excretion in rats were observed at 100 mg/kg i.v. of BIPM, but notat 30 mg/kg i. v.5. BIPM at a concentration of 10-4M did not influence the platelet aggregation by ADP and collagen, the plasma coagulation and the hemolysis test in rabbits.These findings suggest that BIPM seems to be much less potent than imipenem/cilastatin sodium in inducing proconvulsive activity and has no remarkable adverse actions regarding this general pharmacological study. Biapenem (BIPM) の一般薬理作用を検討し, 以下の成績を得た。1. BIPMは, 10~1000mg/kgの静脈内投与でマウスの一般症状に何ら影響を与えず, 100mg/kgの静脈内投与でマウスの自発運動量, thiopental睡眠, 種々の誘発痙攣, ラットの正常体温に影響を与えず, 鎮痛作用も示さなかった。また, 300mg/kg静脈内投与でウサギの自発脳波および行動に何ら影響を及ぼさず, 600mg/kgでマウスでのpentylenetetrazole誘発痙攣増強作用を示さなかった。さらに, マウスに300μg/animal脳室内投与しても行動変化をきたさなかった。一方, imipenem/cilastatin sodiumは, 10/10~300/300mg/kgの静脈内投与でマウス一般症状に影響を与えなかったが, 150/150mg/kg以上の静脈内投与でマウスpentylenetetrazele誘発痙攣を増強し, またimipenemは10μg/animal以上の脳室内投与でマウスに痙攣を惹起した。2. BIPMは, 麻酔犬で100mg/kg静脈内投与により軽度な血圧低下とその後の上昇, 心拍数および大腿動脈血流量の増加を示したが. 呼吸, 心電図には影響を与えず, 30mg/kgでは何ら影響を及ぼさなかった。10-4Mの濃度で. ラット摘出灌流心臓標本に対して影響を与えなかった。3. BIPMは, 10-4g/ml (2.9×10-4M) の濃度でモルモット摘出回腸標本に対して影響を与えず, 100mg/kgの静脈内投与でマウス小腸輸送能, 麻酔モルモット気道抵抗に影響を及ぼさなかった。4. BIPMは, 100mg/kgの静脈内投与でラットでのBSP排泄を遅延させたが, 尿量および尿中電解質排泄に影響を及ぼさなかった。5. BIPMは, 10-4Mの濃度でウサギの血小板凝集および血液凝固に影響を与えず, ウサギ赤血球で溶血性を示さなかった。以上, BIPMの痙攣誘発作用はimipenem/cilastatin sodiumに比較して著しく弱く, また一部で観察された作用も大量投与でのみ発現していることから, 特に問題となるような薬理作用は無いと考えられた。
Author Shiba, Toshiharu
Kitazumi, Kazuhiro
Ishikawa, Tomokazu
Yanaka, Masao
Shikata, Yoshiyuki
Ito, Mami
Author_FL 四方 義幸
石川 智一
柴 富志治
北角 和浩
谷中 正男
伊藤 真美
Author_FL_xml – sequence: 1
  fullname: 柴 富志治
– sequence: 2
  fullname: 北角 和浩
– sequence: 3
  fullname: 石川 智一
– sequence: 4
  fullname: 谷中 正男
– sequence: 5
  fullname: 四方 義幸
– sequence: 6
  fullname: 伊藤 真美
Author_xml – sequence: 1
  fullname: Shiba, Toshiharu
  organization: Biological Research Laboratories, Lederle (Japan) Ltd
– sequence: 1
  fullname: Shikata, Yoshiyuki
  organization: Biological Research Laboratories, Lederle (Japan) Ltd
– sequence: 1
  fullname: Ishikawa, Tomokazu
  organization: Biological Research Laboratories, Lederle (Japan) Ltd
– sequence: 1
  fullname: Yanaka, Masao
  organization: Biological Research Laboratories, Lederle (Japan) Ltd
– sequence: 1
  fullname: Kitazumi, Kazuhiro
  organization: Biological Research Laboratories, Lederle (Japan) Ltd
– sequence: 1
  fullname: Ito, Mami
  organization: Biological Research Laboratories, Lederle (Japan) Ltd
BackLink https://cir.nii.ac.jp/crid/1390001206285330304$$DView record in CiNii
BookMark eNpdkE9PwzAMxSM0JMbYd9iBG3Qkzp82R5hgIE3iAJxDljpbpjat2u6wb0-mcZh2sfXkn5_sd0tGsYlIyCOjc8ZA0ie3xboZttjZ9sC05HMB869921ZYYxyEAaauyJgVhchkocWIjCmlOuNMyRsy7fuwppQxqqCAMXlYYkxO1azd2q62rqmaTXBJ98O-DNjPmjh7CbZNVH1Hrr2tepz-9wn5eXv9Xrxnq8_lx-J5le1A8CHLlfQeLQUPGotyrawuuefgVa4QgFtb8jSmrgCVl1pqic55BsjXOQqn-ITcn3xjCMaFY2VcpycYHK-WnFNORcJ-T9iuH-wGTduF2nYHY7shuArNZU5GgDnP6UKm2M5WbWcw8j_lY3G-
ContentType Journal Article
Copyright Japanese Society of Chemotherapy
Copyright_xml – notice: Japanese Society of Chemotherapy
DBID RYH
DOI 10.11250/chemotherapy1953.42.Supplement4_216
DatabaseName CiNii Complete
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate Biapenemの一般薬理作用
DocumentTitle_FL Biapenemの一般薬理作用
EISSN 1884-5894
EndPage 228
ExternalDocumentID 130004198716
article_chemotherapy1953_42_Supplement4_42_Supplement4_216_article_char_en
GroupedDBID 53G
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
DIK
JSF
JSH
KQ8
RJT
RZJ
ZOHVM
RYH
ID FETCH-LOGICAL-j243t-765ffea02f29e8db6a9d3f32f676e223aad3ea00c8267d9595eccf12e3b7e4c63
ISSN 0009-3165
IngestDate Thu Jun 26 21:31:27 EDT 2025
Wed Sep 03 06:08:54 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Issue Supplement4
Language English
Japanese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-j243t-765ffea02f29e8db6a9d3f32f676e223aad3ea00c8267d9595eccf12e3b7e4c63
OpenAccessLink https://www.jstage.jst.go.jp/article/chemotherapy1953/42/Supplement4/42_Supplement4_216/_article/-char/en
PageCount 13
ParticipantIDs nii_cinii_1390001206285330304
jstage_primary_article_chemotherapy1953_42_Supplement4_42_Supplement4_216_article_char_en
PublicationCentury 1900
PublicationDate 1994-00-00
PublicationDateYYYYMMDD 1994-01-01
PublicationDate_xml – year: 1994
  text: 1994-00-00
PublicationDecade 1990
PublicationTitle CHEMOTHERAPY
PublicationTitleAlternate Chemother.
PublicationTitle_FL CHEMOTHERAPY
Chemother
PublicationYear 1994
Publisher Japanese Society of Chemotherapy
公益社団法人 日本化学療法学会
Publisher_xml – name: Japanese Society of Chemotherapy
– name: 公益社団法人 日本化学療法学会
References 1) Ubukata K, Hikida M, Yoshida M, Nishiki K, Furukawa Y, Tashiro K, Konno M and Mitsuhashi S: In vitro activity of LJC 10, 627, a new carbapenem antibiotic with high stability to dehydropeptidase I. Antimicrob Agent Chemother 34: 994-1000, 1990
5) Sawyer C H, Everett J W and Green J D: The rabbit diencephalon in stereotaxic coordinates. J comp Neurol 101: 801-824, 1954
9) 大野行弘, 広瀬彰, 辻良三, 加藤照文, 中村三孝, Edwards JR, Patel JB: 新規カルバペネム系抗生物質Meropenemの中枢作用に関する行動薬理学的および脳波学的検索. Chemotherapy 40 (S-D: 175-181, 1992
2) 疋田宗生, 森眞彦, 橘田多美: L-627 (Biapenem) のin vitro評価. Chemotherapy 42 (S-4): 91-101, 1994
4) Haley L J and Mc Cormic WG: Pharmacological effects produced by intracerebral invection of drugs in the conscious mouse. Brit J Pharmacol 12: 12-15, 1957
8) 牧栄二, 大村一平. 成瀬友裕, 池田宜二, 浅見照美: 新しいβ-ラクタム系抗生物質lmipenem (MK-0787) とDehydropeptidase-Iの特異的阻害剤Cilastatin Sodium (MK-0791) の併用時における一般薬理作用. Chemotherapy33 (S-4): 329-356, 1985
10) Calandra GB, Brown BK, Grad LC, Ahonkhai V, Wang C and Aziz MA: Review of adverse experiences and tolerability in the first 2, 516 patients treated with imipenem/cilastatin. Am J Med 78 (Suppl. 6A): 73-78, 1985
6) Konzett H and Rössler R: Versuchsanordnung zu untersuchungen an der bronchialmuskulatur. Naunyn-Schmiedeberg's Arch Exp Path Pharmak 195: 71-74, 1940
7) 浅岡宏康, 八巻芳夫, 井沢正典, 杉山史郎, 柴崎義明, 柴田右一, 武田植人, 小枝武美: Amfenacsodium (AHR-5850) の一般薬理作用 (第2報), 摘出平滑筋および消化器系などに及ぼす影響. 応用薬理25: 775-795, 1983
11) Kamei C, Kitazumi K, Tsujimoto S, Yoshida T and Tasaka K: Comparative study of certain antibiotics on epileptogenic property, including (1 Rpi, 5S, 6S)-2-[(6, 7-dihydro-5H-pyrazolo [1, 2-a][1, 2, 4] triazolium-6-yl)] thio-6-[(R)-1-hydroxyethyl]-1-methyl-carbapenem-3-carboxylate (LJC 10, 627), a carbapenem antibiotic with broad antimicrobial spectrum. J Pharmacobio-Dyn 14: 509-517, 1991
3) Hikida M, Kawashima K, Nishiki K, Furukawa F, Nishizawa K, Saito I and Kuwao S: Renal dehydropeptidase-I stability of LJC 10, 627, a new carbapenem antibiotic. Antimicrob Agent Chemother 36: 481-483, 1992
13) 中島光好, 他: 新規静注用抗生剤L-627 (Biapenem) の臨床第I相試験-L-627およびその代謝物の体内動態と安全性の検討-. 薬理と治療22: 1879-1895, 1994
References_xml – reference: 13) 中島光好, 他: 新規静注用抗生剤L-627 (Biapenem) の臨床第I相試験-L-627およびその代謝物の体内動態と安全性の検討-. 薬理と治療22: 1879-1895, 1994
– reference: 9) 大野行弘, 広瀬彰, 辻良三, 加藤照文, 中村三孝, Edwards JR, Patel JB: 新規カルバペネム系抗生物質Meropenemの中枢作用に関する行動薬理学的および脳波学的検索. Chemotherapy 40 (S-D: 175-181, 1992
– reference: 1) Ubukata K, Hikida M, Yoshida M, Nishiki K, Furukawa Y, Tashiro K, Konno M and Mitsuhashi S: In vitro activity of LJC 10, 627, a new carbapenem antibiotic with high stability to dehydropeptidase I. Antimicrob Agent Chemother 34: 994-1000, 1990
– reference: 2) 疋田宗生, 森眞彦, 橘田多美: L-627 (Biapenem) のin vitro評価. Chemotherapy 42 (S-4): 91-101, 1994
– reference: 3) Hikida M, Kawashima K, Nishiki K, Furukawa F, Nishizawa K, Saito I and Kuwao S: Renal dehydropeptidase-I stability of LJC 10, 627, a new carbapenem antibiotic. Antimicrob Agent Chemother 36: 481-483, 1992
– reference: 4) Haley L J and Mc Cormic WG: Pharmacological effects produced by intracerebral invection of drugs in the conscious mouse. Brit J Pharmacol 12: 12-15, 1957
– reference: 10) Calandra GB, Brown BK, Grad LC, Ahonkhai V, Wang C and Aziz MA: Review of adverse experiences and tolerability in the first 2, 516 patients treated with imipenem/cilastatin. Am J Med 78 (Suppl. 6A): 73-78, 1985
– reference: 5) Sawyer C H, Everett J W and Green J D: The rabbit diencephalon in stereotaxic coordinates. J comp Neurol 101: 801-824, 1954
– reference: 8) 牧栄二, 大村一平. 成瀬友裕, 池田宜二, 浅見照美: 新しいβ-ラクタム系抗生物質lmipenem (MK-0787) とDehydropeptidase-Iの特異的阻害剤Cilastatin Sodium (MK-0791) の併用時における一般薬理作用. Chemotherapy33 (S-4): 329-356, 1985
– reference: 7) 浅岡宏康, 八巻芳夫, 井沢正典, 杉山史郎, 柴崎義明, 柴田右一, 武田植人, 小枝武美: Amfenacsodium (AHR-5850) の一般薬理作用 (第2報), 摘出平滑筋および消化器系などに及ぼす影響. 応用薬理25: 775-795, 1983
– reference: 6) Konzett H and Rössler R: Versuchsanordnung zu untersuchungen an der bronchialmuskulatur. Naunyn-Schmiedeberg's Arch Exp Path Pharmak 195: 71-74, 1940
– reference: 11) Kamei C, Kitazumi K, Tsujimoto S, Yoshida T and Tasaka K: Comparative study of certain antibiotics on epileptogenic property, including (1 Rpi, 5S, 6S)-2-[(6, 7-dihydro-5H-pyrazolo [1, 2-a][1, 2, 4] triazolium-6-yl)] thio-6-[(R)-1-hydroxyethyl]-1-methyl-carbapenem-3-carboxylate (LJC 10, 627), a carbapenem antibiotic with broad antimicrobial spectrum. J Pharmacobio-Dyn 14: 509-517, 1991
SSID ssib001106282
ssj0000626693
ssib058492509
ssib005879733
ssib008506721
Score 1.2290839
Snippet General pharmacological properties of biapenem (BIPM), a new carbapenem antibiotic, were studiedand the following results were obtained. 1. BIPM at doses of...
General pharmacological properties of biapenem (BIPM), a new carbapenem antibiotic, were studiedand the following results were obtained.1. BIPM at doses of...
SourceID nii
jstage
SourceType Publisher
StartPage 216
SubjectTerms Biapenem
カルバペネム系抗生物質
一般薬理
Title General pharmacological studies on Biapenem
URI https://www.jstage.jst.go.jp/article/chemotherapy1953/42/Supplement4/42_Supplement4_216/_article/-char/en
https://cir.nii.ac.jp/crid/1390001206285330304
Volume 42
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX CHEMOTHERAPY, 1994/12/28, Vol.42(Supplement4), pp.216-228
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1884-5894
  dateEnd: 19941231
  omitProxy: true
  ssIdentifier: ssj0000626693
  issn: 0009-3165
  databaseCode: KQ8
  dateStart: 19530101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1884-5894
  dateEnd: 20041231
  omitProxy: true
  ssIdentifier: ssj0000626693
  issn: 0009-3165
  databaseCode: DIK
  dateStart: 19530101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfYkBAvCASIjQ3lgbeS0voryeNAQ4VpgKCTxlN0_oiaVU2qLtXE_nrOcZqkBYnBi5vGycnxnc_nO9_PhLw2TBjtQoM0o7hAiSIVJoAMybKx0YICp-BcA-ef5eSCf7oUl10Ev84uqdRQ3_4xr-R_uIr3kK8uS_YfONsSxRt4jfzFEjmM5Z143GBGD5Yd_rTPcvSbA10g4F0OS3xq0TdCHQzCl-nk9NvJ19aQ_T7LFQym5fUsR2LrLjRfwe16kQ_O8GeWr8pOlGb5HG7cK4tyjpWt-oAC5jA4h2soO5eCwwbuFD1O0O7gy3bLaL0lxC6aZLCfW5o0Qf3tz3kYWq8845iHIm7oNdqV054U1SeV1m5PvqU0ZW_-pT5Z_HfVjsYaMkT3muNCgENOcZppyaYtsS0QbRe0G3HnYBnLPXKfOueNs6A_nrXKx0H3bbDi_DSOtkvSnsTnvvUBebNpyds7tAONmis08R12w16R5z27ZfqYPGoWHMGJl54n5J4tnpIN2niwIzlBIzlBWQQbyXlGLj6cTt9PwubYjPCKclaFkRRZZmGEoy-xsVESEsMyRjMZSYvWIIBhWD3SuLKMTCISgcM4G1PLVGS5luw52S_Kwr4gAVXaGBFxxYTmegRJBtIopYWMdcQBDsgP_4Xp0mOjpM1YSHe7J-U07XF_9y_2Vu9VWOHoPiDH2Gmpzl2J65TaZ1pn_DLm4vmHf6l_SR563GvnLjsi-9VqbY_RgKzUq5rxvwCnAXTg
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=General+pharmacological+studies+on+Biapenem&rft.jtitle=CHEMOTHERAPY&rft.au=Shiba+Toshiharu&rft.au=Kitazumi+Kazuhiro&rft.au=Ishikawa+Tomokazu&rft.au=Yanaka+Masao&rft.date=1994&rft.pub=Japanese+Society+of+Chemotherapy&rft.issn=0009-3165&rft.eissn=1884-5894&rft.volume=42&rft.issue=Supplement4&rft.spage=216&rft.epage=228&rft_id=info:doi/10.11250%2Fchemotherapy1953.42.supplement4_216&rft.externalDocID=130004198716
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-3165&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-3165&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-3165&client=summon